Presenting CataloniaBio & HealthTech Blog Post

A new era for the CataloniaBio association of companies and the HealthTech Cluster. Members of the two organisations unanimously passed the motion to merge under the brand CataloniaBio & HealthTech at their respective extraordinary general meetings held in Barcelona yesterday.The headquarters will be located at the Barcelona Science Park. It will promote the convergence of biopharma, MedTech and digital health companies to boost competitiveness and address unmet medical needs 

 

Cebiotex launches a €650,000 crowdfunding campaign to ensure that its oncological treatment reaches paediatrics Blog Post

Cebiotex—with headquarters in the Barcelona Science Park (PCB)—has launched an equity crowdfunding campaign of €650,000 through Capital Cell to ensure that its first drug, CEB-01, used in the local post-surgical treatment of soft tissue sarcomas, also reaches paediatric oncology. CEB-01 is the first therapeutic application of its innovative technology, which are based on nanofibres, for local drug delivery. In the future, however, the company aims to develop new applications for pancreatic and liver cancer, as well as glioblastoma.Since it was formed in 2012, Cebiotex has raised over €2 million from public and private funds. The success of the previous equity crowdfunding campaigns and the participation of impactful social investors has allowed Cebiotex to maintain a paediatric focus as one of the company’s strategic objectives.

 

Genesis Biomed presents its new Genesis Ventures fund Blog Post

Today Genesis Biomed has presented at the Barcelona Science Park a new investment fund, Genesis Ventures, made up of various family offices that are looking to invest in research and business projects in the very early stages in the field of biomedicine. With this initiative, the company based at PCB, wants to help entrepreneurs put together the capital they need for their research in order to later attract series-A corporate funds or venture capital.

 

Entities from PCB promote their international presence at BIO-Europe 2017 Blog Post

From 6 to 8 November, Belin will host BIO-Europe 2017, the largest partnering gathering of the biotech and pharmaceutical industry in Europe and one of the largest in the world. The event, organized by EBD-Group with the collaboration of Biocat –based at the Barcelona Science Park (PCB)– will again draw over 3,800 industry attendees from over 60 countries, representing more than 2,000 companies and It will have a important representation of PCB.

 

Esteve closes the Board of Directors renewal process with the appointment of Joan Esteve as a Chairman Blog Post

Esteve has just announced changes to its corporate governing bodies. In line with the plan approved by the Group’s Board, Albert Esteve will replace Joan Esteve as Chairman of the Board and announces the appointment of Staffan Schüberg, executive vicepresident of the Danish pharmaceutical company Lundbeckas, the group’s Chief Executive Officer. Since 2012, all discovery and preclinical development key units of Esteve are located at the Barcelona Science Park with the latest infrastructure and technology in a top-level academic and scientific environment in Spain.

 

IBEC researchers show that physical forces activate genes involved in cancer Blog Post

IBEC’s researchers at PCB, led by Pere Roca-Cusachs, reveal how forces trigger the expression of certain genes by increasing the activity of a protein called YAP in the nucleus of the cell.  The results of the study, published in Cell, have shown how these forces ‘switch on’ the expression of genes that may result in cancer.

 

Embryotools successfully concludes the first trials on an innovative assisted reproduction technique Blog Post

Embryotools —headquartered at Barcelona Science Park (PCB)— has successfully concluded tests on animal models to validate an innovative assisted reproduction technique known as Maternal Spindle Transfer (MST).  This new technique is a mitochondrial replacement therapy which groups of leading scientists from around the world are studying for the prevention of mitochondrial diseases, which are transmitted maternally and currently have no treatment. Embryotools has been working on this project for over three years in partnership with the PCB-PRBB Animal Facility Alliance and the company Reprogenetics UK, located at Oxford University.

 

An increase in low density lipoproteins would favour insulin resistance Blog Post

A study led by the University of Barcelona proved that low-density proteins (VLDL) can worsen insulin resistance, a disease that favours the development of type 2 diabetes. The study, published in the scientific journal Diabetologia , has been carried out by the research group led by Manuel Vázquez Carrera, researcher from the Department of Pharmacology, Toxicology and Therapeutic Chemistry and the Institute of Biomedicine of the UB (IBUB), located at the Barcelona Science Park.